Altimmune, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 3, 2026, reports on events occurring on February 2, 2026. Altimmune, Inc. (NASDAQ: ALT), a Delaware corporation, announced the scheduling of its 2026 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance events and does not contain financial performance data.
Material Changes
The primary material change is the establishment of the 2026 Annual Meeting date, which differs by more than 30 days from the anniversary of the 2025 Annual Meeting (held September 25, 2025). Consequently, the Company has set specific deadlines for stockholder proposals and director nominations.
Guidance, Outlook, and Corporate Actions
- Annual Meeting Date: Thursday, April 16, 2026.
- Record Date: Friday, March 13, 2026.
- Meeting Format: Expected to be a virtual meeting.
- Stockholder Proposals (Rule 14a-8): Must be received by February 13, 2026.
- Bylaw Proposals/Nominations: Must be received by February 13, 2026.
- Universal Proxy Notice: Stockholders soliciting proxies for director nominees other than the Company's must provide notice by February 15, 2026.
Key Facts for Investor Verification
- Verify the exact time and location of the meeting in the upcoming proxy statement.
- Confirm the deadline of February 13, 2026, for submitting stockholder proposals for inclusion in the proxy statement.
- Note the February 15, 2026, deadline for universal proxy notices regarding director nominations.
- Confirm the record date of March 13, 2026, for voting eligibility.